Rezum water vapor thermal therapy for treatment of lower urinary tract symptoms: A retrospective single-centre analysis from a German high-volume centre.

Autor: Winkler T; Department of Urology and Urologic Oncology, Hannover Medical School (MHH), Hannover, Germany., von Klot CAJ; Department of Urology and Urologic Oncology, Hannover Medical School (MHH), Hannover, Germany., Madersbacher S; Department of Urology, Klinik Favoriten, Vienna, Austria and Department of Urology, Sigmund Freud Private University, Vienna, Austria., Kuczyk MA; Department of Urology and Urologic Oncology, Hannover Medical School (MHH), Hannover, Germany., Wolters M; Department of Urology and Urologic Oncology, Hannover Medical School (MHH), Hannover, Germany.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2023 Jan 06; Vol. 18 (1), pp. e0279883. Date of Electronic Publication: 2023 Jan 06 (Print Publication: 2023).
DOI: 10.1371/journal.pone.0279883
Abstrakt: Objective: Rezum is a minimal invasive surgical treatment for patients with lower urinary tract symptoms (LUTS) related to benign prostatic enlargement (BPE). The aim of our study was to assess safety and efficacy of the Rezum procedure in a consecutive series of patients.
Material and Methods: A retrospective study was performed in a single tertiary care hospital in patients undergoing Rezum procedure between 2018 and 2020. All patients that underwent intervention because of drug-refractory moderate to severe LUTS were assessed. Descriptive outcomes such as symptoms scores (IPSS, IPSS-QoL), peak flow in uroflowmetry (Qmax), post-micturition residual urine volume (PVR) and prostate volume (PVol) were analysed.
Results: In total, 92 Rezum procedures were performed in the observational period. All interventions were competed without device- or procedure relates adverse events. Patients achieved a significant symptom relief as measured in IPSS (50% reduction, p<0.001, n = 35) and IPSS-QoL score (53% reduction, p<0.001, n = 35). Qmax improved by 7.3 ml/s from 10.6 ± 4.2 ml/s to 17.9 ± 9.3 ml/s (p = 0.003, n = 20) were as mean PVR significantly decreased by 136 ml from 175 ± 194.1 to 39 ± 62 ml (p = 0.007, n = 20). PVol significantly decreased by 40.3% from 73.9 ± 41.2 to 44.9 ± 29 ccm (p = 0.024, n = 17). All pre-interventional catheter-depending patients (28.3% of all patient) were catheter independent after six weeks.
Conclusion: Rezum therapy is safe and effective and can be considered a viable treatment option for BPH related LUTS.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Winkler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje